EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

The translational value of ligand‐receptor binding kinetics in drug discovery

Hongli Liu, Haoran Zhang, Adriaan P IJzerman, Dong Guo iD

British Journal of Pharmacology · 2024-11 · 181 (21) · 4117-4129

DOI: 10.1111/bph.16241 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2023-09-30. Written by Hongli Liu and 3 co-authors. Institution: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China. Major MEDLINE topics: Drug Discovery. Cited 29 times so far (Crossref); 81 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Major Basic Research Project of the Natural Science Research Foundation of the Jiangsu Higher Education Institutions.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The translation of in vitro potency of a candidate drug, as determined by traditional pharmacology metrics (such as EC 50 /IC 50 and K D /K i values), to in vivo efficacy and safety is challenging. Residence time, which represents the duration of drug‐target interaction, can be part of a more comprehensive understanding of the dynamic nature of drug‐target interactions in vivo, thereby enabling better prediction of drug efficacy and safety. As a consequence, a prolonged residence time may help in achieving sustained pharmacological activity, while transient interactions with shorter residence times may be favourable for targets associated with side effects. Therefore, integration of residence time into the early stages of drug discovery and development has yielded a number of clinical candidates with promising in vivo efficacy and safety profiles. Insights from residence time research thus contribute to the translation of in vitro potency to in vivo efficacy and safety. Further research and advances in measuring and optimizing residence time will bring a much‐needed addition to the drug discovery process and the development of safer and more effective drugs. In this review, we summarize recent research progress on residence time, highlighting its importance from a translational perspective.

Subjects

MeSH terms (MEDLINE)

Drug DiscoveryHumansAnimalsLigandsKineticsProtein Binding

Author keywords

binding kineticsdrug‐target interactionkoffresidence timetranslation

Substances

Ligands

Authors and institutions

  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
  • Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.

ORCID profiles: Dong Guo

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Major Basic Research Project of the Natural Science Research Foundation of the Jiangsu Higher Education Institutions
  • Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions

Cite

APA

Liu, H., Zhang, H., IJzerman, A. P., & Guo, D. (2024). The translational value of ligand‐receptor binding kinetics in drug discovery. British Journal of Pharmacology, 181(21), 4117-4129. https://doi.org/10.1111/bph.16241

Vancouver

Liu H, Zhang H, IJzerman AP, Guo D. The translational value of ligand‐receptor binding kinetics in drug discovery. British Journal of Pharmacology. 2024;181(21):4117-4129. doi:10.1111/bph.16241

BibTeX
@article{Liu2024,
  author = {Liu, Hongli and Zhang, Haoran and IJzerman, Adriaan P and Guo, Dong},
  title = {The translational value of ligand‐receptor binding kinetics in drug discovery},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {21},
  pages = {4117--4129},
  doi = {10.1111/bph.16241}
}
Start for free →